Akari Therapeutics ADR (AKTX)

$0.53 +0.01 (1.67%)
Market Cap 17.25M
Revenue (ttm) 0.00
Net Income (ttm) -19.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 206,200
Avg Vol 396,094
Day's Range N/A - N/A
Shares Out 32.62M
Stochastic %K 8%
Beta 0.31
Analysts Strong Sell
Price Target $4.53

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology
Sector: Healthcare
Phone: 929 274 7510
Fax: 929 274 7553
Address:
22 Boston Wharf Road, Floor 7, Boston, United States
MTN
MTN Nov. 16 at 6:06 AM
$AKTX lots of new pumpers here, thought there was enough volume to juice a small time profit. Lol.
0 · Reply
MTN
MTN Nov. 16 at 6:05 AM
$AKTX still here, they've flushed hundreds of millions down the toilet so far. Having spoken with Samir, he has a vision. I hope they can execute on it this time. For investors, buyer beware, it is definitely a binary event type of biotech. Also glad to see Hormbech gone, he made key errors with the old pipeline that made me shudder.
1 · Reply
houndsman13
houndsman13 Nov. 14 at 8:18 PM
$AKTX
0 · Reply
stockscan
stockscan Nov. 14 at 4:29 PM
$AKTX https://x.com/AkariTX/status/1989358635831423148?t=PK8V9tPRiruFAc6Y31C85g&s=19
0 · Reply
PirataCodex
PirataCodex Nov. 12 at 6:52 PM
$AKTX going to zero .. abandon ship folks
0 · Reply
PaulLaurent
PaulLaurent Nov. 11 at 7:08 PM
📊🧵 Highest Short Interest Update 💥📛 $XHG $AKTX $MSTY $HSDT $PPBT
0 · Reply
stockscan
stockscan Nov. 10 at 1:48 PM
$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-presents-promising-immuno-oncology-data-its
2 · Reply
PirataCodex
PirataCodex Nov. 10 at 1:39 PM
$AKTX AKTX - maybe we are onto something to solve cancer. STOCK MARKET - lets short this stock down to zero boys
0 · Reply
PirataCodex
PirataCodex Nov. 10 at 1:02 AM
$AKTX $10 tomorrow
1 · Reply
DarrylEvans691
DarrylEvans691 Nov. 5 at 4:46 PM
$AKTX ticks upward following sector rotation. AITX reported that recurring revenue streams continue to expand as adoption of SARA accelerates.
0 · Reply
Latest News on AKTX
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Nov 10, 2025, 8:30 AM EST - 6 days ago

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Nov 4, 2025, 9:25 AM EST - 12 days ago

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Oct 30, 2025, 8:35 AM EDT - 17 days ago

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Akari Therapeutics Announces Launch of CEO Corner Platform

Oct 22, 2025, 9:05 AM EDT - 25 days ago

Akari Therapeutics Announces Launch of CEO Corner Platform

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Oct 15, 2025, 8:30 AM EDT - 4 weeks ago

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Oct 9, 2025, 8:45 AM EDT - 5 weeks ago

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Oct 3, 2025, 9:30 AM EDT - 6 weeks ago

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Sep 24, 2025, 8:45 AM EDT - 7 weeks ago

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Sep 17, 2025, 8:45 AM EDT - 2 months ago

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Akari Therapeutics, Plc (AKTX) Discusses At Virtual Investor Closing Bell Series Call (Transcript)

Sep 10, 2025, 1:44 PM EDT - 2 months ago

Akari Therapeutics, Plc (AKTX) Discusses At Virtual Investor Closing Bell Series Call (Transcript)

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 6:45 AM EDT - 2 months ago

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Sep 3, 2025, 8:30 AM EDT - 2 months ago

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 3 months ago

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Jul 29, 2025, 9:15 AM EDT - 3 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Jul 23, 2025, 8:55 AM EDT - 4 months ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 4 months ago

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 25, 2025, 9:00 AM EDT - 5 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Jun 18, 2025, 8:50 AM EDT - 5 months ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 29, 2025, 9:15 AM EDT - 6 months ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025, 9:00 AM EDT - 6 months ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 6 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:05 AM EDT - 6 months ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

May 1, 2025, 8:45 AM EDT - 7 months ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Apr 22, 2025, 9:05 AM EDT - 7 months ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Mar 20, 2025, 8:35 AM EDT - 8 months ago

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Mar 3, 2025, 9:00 AM EST - 9 months ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 9 months ago

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Feb 3, 2025, 8:00 AM EST - 10 months ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Akari Therapeutics Announces Key Leadership Appointments

Dec 18, 2024, 8:51 AM EST - 11 months ago

Akari Therapeutics Announces Key Leadership Appointments

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Dec 16, 2024, 9:05 AM EST - 11 months ago

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Nov 14, 2024, 4:15 PM EST - 1 year ago

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Nov 8, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 19, 2024, 4:15 PM EDT - 1 year ago

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

May 16, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

May 1, 2024, 8:01 AM EDT - 1 year ago

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

May 1, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Apr 1, 2024, 6:30 AM EDT - 1 year ago

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Mar 5, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Jan 2, 2024, 8:00 AM EST - 2 years ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Akari Therapeutics to Present at Biotech Showcase 2024

Dec 14, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics to Present at Biotech Showcase 2024

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Dec 1, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 16, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 6, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Sep 29, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Akari Therapeutics to Present at Emerging Growth Conference

Sep 27, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Present at Emerging Growth Conference

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

MTN
MTN Nov. 16 at 6:06 AM
$AKTX lots of new pumpers here, thought there was enough volume to juice a small time profit. Lol.
0 · Reply
MTN
MTN Nov. 16 at 6:05 AM
$AKTX still here, they've flushed hundreds of millions down the toilet so far. Having spoken with Samir, he has a vision. I hope they can execute on it this time. For investors, buyer beware, it is definitely a binary event type of biotech. Also glad to see Hormbech gone, he made key errors with the old pipeline that made me shudder.
1 · Reply
houndsman13
houndsman13 Nov. 14 at 8:18 PM
$AKTX
0 · Reply
stockscan
stockscan Nov. 14 at 4:29 PM
$AKTX https://x.com/AkariTX/status/1989358635831423148?t=PK8V9tPRiruFAc6Y31C85g&s=19
0 · Reply
PirataCodex
PirataCodex Nov. 12 at 6:52 PM
$AKTX going to zero .. abandon ship folks
0 · Reply
PaulLaurent
PaulLaurent Nov. 11 at 7:08 PM
📊🧵 Highest Short Interest Update 💥📛 $XHG $AKTX $MSTY $HSDT $PPBT
0 · Reply
stockscan
stockscan Nov. 10 at 1:48 PM
$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-presents-promising-immuno-oncology-data-its
2 · Reply
PirataCodex
PirataCodex Nov. 10 at 1:39 PM
$AKTX AKTX - maybe we are onto something to solve cancer. STOCK MARKET - lets short this stock down to zero boys
0 · Reply
PirataCodex
PirataCodex Nov. 10 at 1:02 AM
$AKTX $10 tomorrow
1 · Reply
DarrylEvans691
DarrylEvans691 Nov. 5 at 4:46 PM
$AKTX ticks upward following sector rotation. AITX reported that recurring revenue streams continue to expand as adoption of SARA accelerates.
0 · Reply
UgoGreg
UgoGreg Nov. 5 at 1:56 PM
$AKTX https://youtu.be/xX3Jc6qCRAc
0 · Reply
stockanalysis_
stockanalysis_ Nov. 5 at 1:19 PM
Premarket Losers: $BHVN $TREX $SNBR $AKTX $CLOV Bookmark this page: https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading
0 · Reply
lamineyamal31
lamineyamal31 Nov. 5 at 9:08 AM
$AKTX
0 · Reply
Reesifer
Reesifer Nov. 5 at 1:00 AM
$AKTX got more at .625
0 · Reply
Reesifer
Reesifer Nov. 5 at 12:55 AM
$AKTX added .6401
1 · Reply
alromofi
alromofi Nov. 4 at 11:29 PM
$AKTX Fkinn POS
0 · Reply
isaacwilliams33
isaacwilliams33 Nov. 4 at 10:39 PM
$AKTX afterhours crap out 💩 look for this to rebound tomorrow
1 · Reply
PirataCodex
PirataCodex Nov. 4 at 10:32 PM
$AKTX 4th stock in a row now that ive chased only to have the pump sell off to down below the days low... un fucking believable.... AI algos must be behind this nonsense.. ive obliterated by trading account and my lively hood
0 · Reply
DaSqueeza
DaSqueeza Nov. 4 at 10:02 PM
$AKTX main profit goes to the short sellers
2 · Reply
MapNeeds
MapNeeds Nov. 4 at 10:02 PM
$CMBM $AKTX
0 · Reply
Aburose
Aburose Nov. 4 at 9:52 PM
$AKTX don’t trust any of those companies announced any more even if it is super ad
0 · Reply
Aburose
Aburose Nov. 4 at 9:50 PM
$AKTX scamer
0 · Reply